Loading
A phase 3 trial of Pembrolizumab in non-small-cell lung cancer, run by Celltrion, active and no longer recruiting.
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer is a phase 3 interventional study registered as NCT06939595 by Celltrion, with 225 participants enrolled, started 2025-01-30 and due to reach its primary completion in 2027-02. Interventions recorded: CT-P51 and EU-approved Keytruda.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.